Common Side Effects and Their Frequencies
Icosapent ethyl (Vascepa), used to lower triglycerides, has side effects reported in clinical trials like REDUCE-IT. Most are mild, with gastrointestinal issues leading. Here's the frequency from placebo-controlled data:
- Bleeding events (e.g., epistaxis, gingival, bruising): 12% with icosapent vs. 9.9% placebo (relative risk 1.2). Serious bleeding rare at 2.7% vs. 2.3%.[1][2]
- Palpitations: 5.3% vs. 4.0% placebo.[1]
- Atrial fibrillation: 5.2% vs. 3.9% placebo.[1]
- Gastrointestinal disorders (e.g., diarrhea, nausea, constipation): Around 5-9% across categories, similar to placebo.[2]
- Rash or skin eruptions: 1.8-2.2% vs. 1.2% placebo.[1]
Placebo-adjusted rates are low (often <2%), and discontinuation due to side effects was 4.3% vs. 3.3% placebo.[1]
How REDUCE-IT Trial Data Was Collected
The pivotal REDUCE-IT trial tracked 8,179 high-risk patients on statins over 4.9 years median follow-up. Adverse events were captured via systematic reporting, with frequencies calculated as percentages of patients experiencing each event. No dose-response spike noted at 4g/day standard dose.[1][2]
Rare but Serious Side Effects
- Hemorrhagic stroke: 0.3% vs. 0.1% placebo (not statistically significant).[1]
- Muscle spasms or arthralgia: <2% excess risk.[2]
- Hypersensitivity reactions: <1%, including anaphylaxis in post-marketing reports.[3]
No increased cancer or infection risk observed.[1]
Patient Factors Influencing Side Effect Rates
Elderly patients (>65 years) saw slightly higher bleeding (11% vs. 10% placebo). Those on antiplatelets/anticoagulants had elevated bleeding risk (12.5% vs. 10%). Asian subgroups reported more rash (4.3% vs. 1.7%).[1][2]
Comparison to Other Fish Oil Products
Unlike over-the-counter EPA/DHA mixes, pure icosapent shows lower GI upset (9% vs. up to 20% in some OTC trials) due to no DHA. Similar profile to fenofibrate but fewer myopathies.2
Long-Term Use and Monitoring
Over 5 years, side effect rates stayed stable without cumulative increase. FDA recommends monitoring for bleeding in at-risk patients; no routine labs needed beyond lipids.[3]
Sources
[1]: REDUCE-IT trial (NEJM 2019) - nejm.org/doi/full/10.1056/NEJMoa1812792
[2]: Vascepa prescribing information - vascepa.com
[3]: FDA label updates - accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf